Literature DB >> 24674413

Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate.

William A Hall1, Lauren Colbert2, Dana Nickleach3, Joseph Shelton2, David M Marcus2, Jeffrey Switchenko3, Peter J Rossi2, Karen Godette2, Sherrie Cooper2, Ashesh B Jani2.   

Abstract

PURPOSE: Novel techniques to deliver intensity modulated radiation therapy (IMRT) have resulted in improved treatment efficiency and dosimetric endpoints. We aimed to compare acute gastrointestinal (GI) and genitourinary (GU) toxicity in patients treated for adenocarcinoma of the prostate (ACP) using volumetric modulated arc therapy (VMAT). METHODS AND MATERIALS: A total of 122 (71 IMRT and 51 VMAT) ACP patients treated from 2004 to 2011 with definitive external beam radiation therapy were analyzed. Dose-volume histogram endpoints (V40, V65, V70, and V75 of the bladder and rectum) were collected for each patient. Median follow-up for patients treated with VMAT was 269 days versus IMRT was 1121 days. Acute Common Toxicity Criteria for Adverse Events (CTCAE) GI and GU toxicity scores, obtained during each weekly treatment check, were compared across cohorts. The univariate (UV) association between the covariates and outcomes was assessed and multivariable (MV) cumulative logit models were fit for each outcome.
RESULTS: Median patient age was 68 years and median prostate-specific antigen was 8.3. Both bladder and rectal V40, V65, V70, and V75 were all higher in the IMRT group versus the VMAT group (P < .05), which was likely influenced by larger planning target volumes in the IMRT group. The VMAT group had significantly lower rates of acute GU and acute GI CTCAE toxicity on UV association analysis. On MV analysis, VMAT remained independently associated with acute GU (odds ratio [OR], 0.18; 95% confidence interval [CI], 0.07-0.44; P < .001) and GI (OR, 0.16; 95% CI, 0.07-0.41; P < .001) toxicity.
CONCLUSIONS: VMAT appears to be independently associated with lower rates of acute GI and GU toxicity when compared with traditional IMRT. Further exploration of toxicity improvements associated with VMAT use in the definitive treatment of ACP is needed.
Copyright © 2013 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2013        PMID: 24674413     DOI: 10.1016/j.prro.2013.01.003

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  7 in total

1.  Volumetric modulated arc therapy in prostate cancer patients with metallic hip prostheses in a UK centre.

Authors:  Wee Loon Ng; John Brunt; Simon Temple; Mohammed Saipillai; Anoop Haridass; Helen Wong; Zafar Malik; Chinnamani Eswar
Journal:  Rep Pract Oncol Radiother       Date:  2015-04-14

2.  Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer.

Authors:  Kentaro Ishii; Ryo Ogino; Yukinari Hosokawa; Chiaki Fujioka; Wataru Okada; Ryota Nakahara; Ryu Kawamorita; Takuhito Tada; Yoshiki Hayashi; Toshifumi Nakajima
Journal:  Br J Radiol       Date:  2016-03-31       Impact factor: 3.039

3.  Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy.

Authors:  Leif Hendrik Dröge; Hanne Elisabeth Weber; Manuel Guhlich; Martin Leu; Lena-Christin Conradi; Jochen Gaedcke; Steffen Hennies; Markus Karl Herrmann; Margret Rave-Fränk; Hendrik Andreas Wolff
Journal:  BMC Cancer       Date:  2015-10-20       Impact factor: 4.430

4.  Rectal Dose Is the Other Dosimetric Factor in Addition to Small Bowel for Prediction of Acute Diarrhea during Postoperative Whole-Pelvic Intensity-Modulated Radiotherapy in Gynecologic Patients.

Authors:  Eng-Yen Huang; Yu-Ming Wang; Shih-Chen Chang; Shu-Yu Liu; Ming-Chung Chou
Journal:  Cancers (Basel)       Date:  2021-01-28       Impact factor: 6.639

5.  Volumetric Modulated Arc Therapy of the Pelvic Lymph Nodes to the Aortic Bifurcation in Higher Risk Prostate Cancer: Early Toxicity Outcomes.

Authors:  Gina Hesselberg; Gerald Fogarty; Lauren Haydu; Nicole Dougheney; Phillip Stricker
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411

6.  Intensity-modulated radiotherapy for whole pelvis irradiation in prostate cancer: A dosimetric and plan robustness study between photons and protons.

Authors:  Ashley L K Ong; K W Ang; Zubin Master; Sharon M M Wong; Jeffrey K L Tuan
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2018-04-03

7.  Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer.

Authors:  Antonio Lazo; Alejandro de la Torre-Luque; Gregorio Arregui; Daniel Rivas; Ana Serradilla; Joaquin Gómez; Francisca Jurado; María Isabel Núñez; Escarlata López
Journal:  Biology (Basel)       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.